Germany Cell & Gene Therapy Market- Focused Insights 2023-2028

Published Date :  MAR 2023

price

$0
$0

Get this report for lesser with our subscription services

While subscription services provide a hassle-free experience and cost savings.

GO TO SECTION:

Speak With Us

Want to know more about the report or any specific requirement?

About The Report

DOWNLOAD SAMPLE

Reveals In-depth Insights of the Germany Cell & Gene Therapy Market of 3 Major Segments with Extensive Charts & Tables

Why This Report?

  • Short/Crisp, off-the-shelf reports intended to provide quick insights
  • Provide Bird’s eye view of market segments at country & regional level
  • Draw conclusions about markets and readily extract/integrate the data to use in presentations
  • Navigate highly researched data & in-depth insights in less than 1 hour
  • Compare similar reports market data across countries & regions


Cell and gene therapies are part of advanced therapy medicinal products (ATMPs). ATMPs are medicines that are developed based on genes, tissues and cells. The introduction of many novel ATMPs in recent years, especially cell and gene therapies changed the treatment dynamics of many complex and challenging diseases like cancer and genetic disorders. Government, as well as industrial and academic financing and collaboration among small and large biopharmaceutical companies, offer significant growth to the market in the coming years. 

Key Highlights 

  • The Germany cell and gene therapy market was valued at $0.34 billion in 2022 and is projected to reach at $3.44 billion in 2028, with a compound annual growth rate (CAGR) of 40.15%, during the study period. 
  • Among all commercial cell & gene therapies, Zolgensma is the first and only product to achieve the blockbuster drug tag. Zolgensma generated a revenue of $1.37 billion in 2022 and has the potential to reach around $5.00 billion by 2026. 
  • Drug developers are prioritizing to develop and commercialize CAR-T cell-based gene therapies. Globally, more than 1,000 clinical trials are being conducted on CAR T-cell therapies, of which atleast 500 clinical trials are for cancer alone. Kymriah (Novartis), Yescarta (Gilead Sciences), Tecartus (Gilead Sciences), Breyanzi (Bristol Myers Squibb), Abecma (Bristol Myers Squibb) and Carvykti (Janssen Biotech / Legend Biotech) are the commercial CAR-T therapies available in the market. 
  • In 2022, Germany was the first-largest market in Europe, followed by France and the UK. The market is majorly driven by an increase in target patient population, regulatory body support, and higher access to healthcare due to well-established healthcare infrastructure. 
  • The European Medicines Agency (EMA) has approved more than nineteen cell and gene therapy drugs, but the new product pipeline has approximately 193 investigational therapies, with more than half of these in Phase 2 clinical trials. Oncology and rare diseases continue to be the top areas targeted by gene therapies from preclinical through pre-registration. 
  • Approximately 261 clinical trials are under investigation for various cell and gene therapies in Germany. This increase could be because of an improvement in funding for cell and gene therapy. The industry sponsored trials are continued to dominate with a share of 88.51%. 
  • Novartis, Gilead Sciences, Spark Therapeutics, Amgen, Orchard Therapeutics, Bristol-Myers Squibb, BioMarin, PTC Therapeutics, and Organogenesis are the leading players in the Europe cell and gene therapy market. The market offers tremendous growth opportunities for existing and future/emerging players because of the presence of a large pool of target patient populations with chronic diseases such as cancer, genetic and rare diseases, and other complex disorders. 



solution

Client Oriented Solutions

Arizton provides in-depth market insights and intelligence across various sectors, including Automotive & Mobility, Data Centers, Consumer Goods, and Healthcare & Lifesciences.

marktet

Analytical Approach

Arizton focuses on providing information related to key issues facing the industry, Existing market landscape, regulatory concerns, risk & opportunities, technology evolution, future commercial potential.

folder

Comprehensive Data Repository

The reports provide historical and forecast data for 20+ key countries worldwide. We track product approvals/launches, M&A activities, and collaboration/partnership activities.

application

Publication Analysis

Arizton delivers timely industry updates and customized insights by analyzing peer-reviewed research and business publications.

price

$0
$0

Get this report for lesser with
our subscription services

Summary

This report offers market size & forecast data for cell & gene therapy market in Germany. The report covers commercial cell & gene therapy products, such as conventional cell therapies, CAR-T cell therapies, gene therapies, cell-based immunotherapies, and oncolytic virus therapies. Cell therapies sourced from mesenchymal stem cells, cell-based immune modulation therapies, and cell/tissue-based products derived from patients’ blood are also covered in the report. Tissue-engineered products and tissue grafts/scaffolds with synthetic mechanical structures are excluded from the scope of the report. This report provides a comprehensive and current market scenario of the Germany cell & gene therapy market, including the Germany cell & gene therapy market size, anticipated market forecast, relevant market segmentations, and industry trends. 



Report Preview

Germany Cell & Gene Therapy Market Report by AriztonDOWNLOAD SAMPLE

Please Note : Arizton critically analyzes the industry and market sectors to provide reliable and valuable market intelligence. The research-based knowledge empowers clients to formulate intelligent strategies, resulting in creative, cost-effective, and efficient execution.

Table Of Contents

  • Executive Summary 
  • Introduction 
  • Key Findings 
  • Key Developments 


  • Germany: Projected Revenue of Cell & Gene Therapy (2022-2028; $Billions) 
  • Product type 
  • Application type 
  • End-user type 



  • Cell & Gene Therapy Market Drivers 
  • Cell & Gene Therapy Market Trends 
  • Cell & Gene Therapy Market Constraints 




  • Cell & Gene Therapy - Marketed Drugs Overview 
  • Cell & Gene Therapy - Pipeline Drugs Overview 
  • Cell & Gene Therapy - Competitive Landscape 
  • Cell & Gene Therapy - Key Players 
  • Cell & Gene Therapy - Key Company Profiles 
  • Cell & Gene Therapy - Mergers & Acquisitions 
  • Cell & Gene Therapy - Key Strategic Recommendations 





  • Pricing, Reimbursement and Market Access 
  • Contract Manufacturing Organizations (CMOs) 
  • Regulatory Landscape and Policies 






  • Research Methodology 
  • Abbreviations 
  • About Arizton 







  • Exhibit 1: Projected Revenue of Cell & Gene Therapy Market in Germany (2022 – 2028) 
  • Exhibit 2: Projected Revenue of Cell & Gene Therapy Market in Germany by Product type (2022 – 2028) 
  • Exhibit 3: Projected Revenue of Cell & Gene Therapy Market in Germany by Application type (2022 – 2028) 
  • Exhibit 4: Projected Revenue of Cell & Gene Therapy Market in Germany by End-user type (2022 – 2028) 
  • Exhibit 5: Marketed Drugs Overview in Cell & Gene Therapy Market 
  • Exhibit 6: Pipeline Drugs Overview in Cell & Gene Therapy Market 








Table 1: Key Market Trends in Cell & Gene Therapy Market 

Table 2: Key Market Enablers in Cell & Gene Therapy Market 

Table 3: Key Market Constraints in Cell & Gene Therapy Market 

Table 4: Recent Approvals in Cell & Gene Therapy Market 

Table 5: Near-term Approvals in Cell & Gene Therapy Market 

Table 6: Strategic Recommendations in Cell & Gene Therapy Market 

Table 7: Mergers & Acquisitions in Cell & Gene Therapy Market 

Table 8: Pricing & Reimbursement of Cell & Gene Therapy Market 








Interested in this report?

Other Related Reports

Europe Cell & Gene Therapy Market - Focused Insights 2023-2028

$ 1800

Navigate the complexities of the Europe Cell & Gene Therapy Market with our comprehensive report. This analysis allows you to identify emerging contenders with robust product portfolios and craft effective counter strategies to secure your competitive edge.

View

Europe Wound Care Market - Focused Insights 2023-2028

$ 1800

Take advantage of our in-depth market insights of the Europe wound care market. Stay ahead of the curve by identifying emerging players with potentially strong service portfolios, and devise counter strategies to gain a competitive edge. Invest in our expert guidance to navigate your business to new heights of success.

View

US Wound Care Market - Focused Insights 2023-2028

$ 1500

Experience the cutting-edge insights of the wound care market in the US. Investments in R&D and the launch of pioneering wound care products and devices are pivotal in boosting sales growth and increasing market shares in the fiercely competitive US wound care market.

View

Frequently Asked Questions

The Germany cell and gene therapy market is projected to reach at $3.44 billion in 2028.

Reach us at enquiry@arizton.com for a free sample report.

This report offers market size & forecast data for cell & gene therapy market in Germany. The report covers commercial cell & gene therapy products, such as conventional cell therapies, CAR-T cell therapies, gene therapies, cell-based immunotherapies, and oncolytic virus therapies.

This report offers market size & forecast for Product type ▪ Cell therapy ▪ Gene therapy Application type ▪ Oncology ▪ Genetic Disorders ▪ Dermatology ▪ Musculoskeletal ▪ Others End-user type ▪ Hospitals ▪ Cancer Care Centers ▪ Others

Download Free Sample

Download free market research reports by Focus Reports covering, industry overview, market size, market share.

Speak with our analyst

Download free market research reports by Arizton covering, industry overview, market size, market share, markets trends.

Our Clients

client2
client3
client4
client5

Interested in this report?

DOWNLOAD SAMPLE